Subtopic Deep Dive

Idiopathic Pulmonary Fibrosis Diagnosis
Research Guide

What is Idiopathic Pulmonary Fibrosis Diagnosis?

Idiopathic Pulmonary Fibrosis Diagnosis encompasses multidisciplinary approaches using high-resolution CT patterns, histopathological criteria, and clinical guidelines to confirm IPF in patients with progressive fibrosing interstitial pneumonia of unknown cause.

Diagnosis relies on UIP pattern on HRCT or biopsy, excluding known causes of ILD (Wells and Hirani, 2008; 853 citations). Multidisciplinary discussion integrates imaging, pathology, and physiology per guidelines. Over 50 papers detail diagnostic algorithms and biomarker validation.

15
Curated Papers
3
Key Challenges

Why It Matters

Early IPF diagnosis enables antifibrotic therapy like nintedanib, slowing FVC decline and improving survival (Richeldi et al., 2014; 4357 citations). Accurate differentiation from other ILDs prevents misdiagnosis in 10-30% of cases (Wells and Hirani, 2008). Global incidence data guide screening programs (Hutchinson et al., 2015; 896 citations).

Key Research Challenges

HRCT Pattern Variability

Distinguishing UIP from NSIP or fibrotic hypersensitivity pneumonitis on HRCT shows inter-reader agreement of 60-80%. Wells and Hirani (2008) outline criteria but validation cohorts vary. Automated AI scoring tools lack standardization.

Biomarker Validation Gaps

Non-invasive markers like KL-6 or SP-D require large prospective trials for specificity >90%. Song et al. (2010) highlight acute exacerbation risks complicating diagnosis. Few studies exceed 500 patients.

Multidisciplinary Consensus

MDT diagnosis achieves 90% confidence but lacks formalized scoring (Wells and Hirani, 2008). Regional guideline variations affect reproducibility. Training datasets for ML diagnostics are underrepresented.

Essential Papers

1.

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · 2014 · New England Journal of Medicine · 4.4K citations

In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea,...

2.

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia et al. · 2019 · EBioMedicine · 1.1K citations

4.

Update of EULAR recommendations for the treatment of systemic sclerosis

Otylia Kowal‐Bielecka, Jaap Fransen, Jérôme Avouac et al. · 2016 · Annals of the Rheumatic Diseases · 1.1K citations

5.

Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity

Vincent Cottin, Hilario Nunès, Pierre‐Yves Brillet et al. · 2005 · European Respiratory Journal · 990 citations

The syndrome resulting from combined pulmonary fibrosis and emphysema has not been comprehensively described. The current authors conducted a retrospective study of 61 patients with both emphysema ...

6.

Pirfenidone in idiopathic pulmonary fibrosis

H. Taniguchi, Masahito Ebina, Yasuhiro Kondoh et al. · 2009 · European Respiratory Journal · 929 citations

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial was conducte...

7.

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review

John W. Hutchinson, Andrew Fogarty, Richard C. Hubbard et al. · 2015 · European Respiratory Journal · 896 citations

As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally. This study aims to systematically assess all ...

Reading Guide

Foundational Papers

Start with Wells and Hirani (2008; 853 citations) for ILD diagnostic framework including HRCT/BAL criteria, then Richeldi et al. (2014; 4357 citations) for IPF-specific FVC correlations.

Recent Advances

Study Hutchinson et al. (2015; 896 citations) for global epidemiology informing screening, Song et al. (2010; 770 citations) for exacerbation diagnostics.

Core Methods

HRCT UIP scoring, MDT integration, FVC/PaO2 physiology, biopsy histopathology (Wells and Hirani, 2008).

How PapersFlow Helps You Research Idiopathic Pulmonary Fibrosis Diagnosis

Discover & Search

Research Agent uses searchPapers('IPF diagnosis HRCT UIP') to retrieve Wells and Hirani (2008; 853 citations), then citationGraph reveals 500+ citing works on guideline updates, and findSimilarPapers expands to Cottin et al. (2005) for CPFE differentials.

Analyze & Verify

Analysis Agent applies readPaperContent on Richeldi et al. (2014) to extract FVC diagnostic correlations, verifyResponse with CoVe checks claims against Hutchinson et al. (2015) incidence data, and runPythonAnalysis computes meta-analysis survival curves using GRADE for evidence grading on diagnostic accuracy.

Synthesize & Write

Synthesis Agent detects gaps in biomarker validation across 20 papers, flags contradictions in HRCT specificity (Wells 2008 vs. Song 2010), then Writing Agent uses latexEditText for diagnostic flowchart, latexSyncCitations integrates 15 references, and latexCompile generates camera-ready review section.

Use Cases

"Analyze survival data from IPF diagnostic cohorts in recent papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Richeldi 2014 + Song 2010 FVC data) → matplotlib Kaplan-Meier plot with GRADE B evidence.

"Draft IPF diagnostic algorithm LaTeX figure with citations"

Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure (HRCT/UIP flowchart) → latexSyncCitations (Wells 2008, Richeldi 2014) → latexCompile → PDF with embedded UIP criteria.

"Find code for IPF HRCT image analysis from papers"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable PyTorch HRCT segmentation model trained on 1000+ IPF scans.

Automated Workflows

Deep Research workflow scans 50+ IPF diagnosis papers via searchPapers → citationGraph → structured report with GRADE-graded HRCT evidence tables. DeepScan applies 7-step CoVe to validate biomarker claims from Taniguchi et al. (2009) against global incidence (Hutchinson 2015). Theorizer generates hypotheses on ML-augmented MDT from Wells (2008) guidelines + Cottin (2005) CPFE patterns.

Frequently Asked Questions

What defines IPF diagnosis?

IPF diagnosis requires UIP pattern on HRCT or biopsy, exclusion of other causes, and MDT consensus (Wells and Hirani, 2008).

What are key diagnostic methods?

HRCT shows subpleural basal reticulation and honeycombing; surgical lung biopsy confirms if HRCT inconclusive (Wells and Hirani, 2008).

What are seminal papers?

Wells and Hirani (2008; 853 citations) provide ILD guidelines; Richeldi et al. (2014; 4357 citations) link diagnosis to nintedanib outcomes.

What open problems exist?

Non-invasive biomarkers lack prospective validation; HRCT AI tools need diverse training data; MDT reproducibility varies regionally.

Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Idiopathic Pulmonary Fibrosis Diagnosis with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers